Scott Jeffers
Chief Technology Officer, GenSight Biologics
I impact human health. Losing my father to lung cancer, and my grandmother and uncle to pancreatic cancer, I feel compelled to eradicate human suffering. Gene therapy will extend and improve life and cure the incurable. Throughout my international research career, I have worked on numerous projects expanding the understanding of viruses (Ebola, RVFV, CCHFV, Hantaan, and SARS). I hold two US patents for gene therapy vectors. I have worked with numerous biotech and pharma companies to bring novel gene therapies to the clinic (process development, scale-up, and tech transfer, regulatory filings) both at clinical and commercial stages, for rare monogenetic diseases. In my increasing responsibility roles, I lead teams that utilize novel techniques and approaches including single-use suspension and adherent cell bioreactors, and adherent cell culture in Hyperstacks and CF, to produce viral vectors, such as AAV, Adenovirus, Lentivirus, Retrovirus, Herpes virus. My teams purify viral vectors using many different modalities (membrane chromatography, affinity chromatography, IEX chromatography, tangential flow filtration, depth filtration, and centrifugation). I simultaneously manage multiple projects, lead multi-disciplinary teams, work with cross-functional teams (upstream and downstream manufacturing and process development, QC, QA, and Engineering) and collaborate with leaders across the globe.
